Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®
Monday 22 July, 2024 Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States.With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol).Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability…
Monday 22 July, 2024
Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States.With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol).Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability…
Read More
About Author
